Background:
Stereotactic body radiation therapy (SABR) is a type of radiation therapy that uses special equipment to deliver radiation to tumors with high precision. This method may kill tumor cells with few radiation doses over a shorter period, causing less damage to normal tissue.
Immunotherapy, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, help the body’s immune system attack the cancer cells, interfering with the ability of the tumor cells to grow and spread.
Axitinib, cabozantinib, and lenvatinib are a class of medications that stop the formation of blood vessels that bring oxygen and nutrients to the tumor cells. This may slow the growth and spread of the tumor.
The Trial:
This study will investigate the effectiveness of adding SABR to immunotherapy, compared to immunotherapy alone, in patients with metastatic kidney cancer that has not been removed by surgery. Researchers will look at how well this combination helps delay the need for surgery and prevents the cancer from getting worse.
Kidney cancer participants will be randomly assigned to one of the below treatment regimes:
- Standard immunotherapy
- Standard immunotherapy + SABR
This study is not “blinded”, which means both you and your doctor will be aware of which treatment you are receiving.
Basic Eligibility:
- Metastatic kidney cancer (cancer has spread) or cannot be removed by surgery
- Primary kidney tumor is 20cm or smaller
Additional eligibility criteria will apply. Please speak to your doctor.
Hospital / Cancer Centre | Principal Investigator | Location | Trial Status |
---|---|---|---|
Hospital / Cancer CentrePrincess Margaret Cancer Centre | Principal InvestigatorNot Given | LocationToronto, ON | Trial StatusSuspended |
Hospital / Cancer CentreCHU de Québec L’Hotel-Dieu de Quebec (HDQ) | Principal InvestigatorNot Given | LocationQuebec, QC | Trial StatusSuspended |